Montelukast thin film - Qilu Pharmaceutical
Alternative Names: Montelukast sodium oral thin film - Qilu PharmaceutucalLatest Information Update: 28 May 2024
At a glance
- Originator Qilu Pharmaceutical
- Class Acetates; Anti-inflammatories; Antiasthmatics; Antidementias; Bronchodilators; Neuroprotectants; Nootropics; Quinolines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 May 2024 No recent reports of development identified for clinical-Phase-Unknown development in Unspecified(In volunteers) in China (PO, Film)
- 14 May 2019 Qilu Pharmaceutical completes pharmacokinetic and bioequivalence clinical trial in Unspecified (In volunteers) in China (PO) (NCT05528198)
- 14 May 2019 Qilu Pharmaceutical completes pharmacokinetic and bioequivalence clinical trial in Unspecified (In volunteers) in China (PO) (NCT05531994)